- PII
- 10.31857/S0044453723080046-1
- DOI
- 10.31857/S0044453723080046
- Publication type
- Status
- Published
- Authors
- Volume/ Edition
- Volume 97 / Issue number 8
- Pages
- 1218-1224
- Abstract
- A study is performed of the effect native and polymeric β-cyclodextrins have on the solubility and membrane permeability of baricitinib, a new generation immunomodulator. It is found that native and polymeric β-cyclodextrins exhibit the same solubilizing effect in relation to baricitinib, while their effect on the membrane permeability of the drug differs. The increased solubility of baricitinib is due to the formation of inclusion complexes that have the same stability but are enthalpy-entropy stabilized in native β-cyclodextrin and enthalpy stabilized in polymeric β-cyclodextrin. The effect cyclodextrins on baricitinib’s coefficients of permeability of through a model membrane is discussed in terms of complexation, changes in the viscosity of the medium, and the state of the water boundary layer near the membrane’s surface.
- Keywords
- растворимость иммуномодулятор барицитиниб природный и полимерный β‑циклодекстрины
- Date of publication
- 13.09.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 15
References
- 1. Aletaha D., Neogi T., Silman A.J. et al. // Arthritis Rheumatol. 2010. V. 62. P. 2569. https://doi.org/10.1002/art.27584
- 2. Drug Approval Package: Olumiant (baricitinib). 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000TOC.cfm
- 3. Olumiant product information, European public assessment report. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant#authorisation-details-section.
- 4. Garibyan A.A., Delyagina E.S., Agafonov M.A. et al. // J. Mol. Lig. 2022. V. 360. P. 119548. https://doi.org/10.1016/j.molliq.2022.119548
- 5. Alshetaili A.S. // Z. Phys. Chem. 2018. V. 233. https://doi.org/10.1515/zpch-2018-1323
- 6. FDA Briefing, Arthritis Advisory Committee Meeting document, AAC Brief NDA 207924 (2018).
- 7. Ansari M.J., Alschahrani S.M. // Saudi Pharm. J. 2019. V. 27. P. 491. https://doi.org/10.1016/j.jsps.2019.01.012
- 8. Zheng X.-Q., Huang J.-F., Lin J.-L. et al. // Colloids Surf. B. 2021. V. 199. P. 111532. https://doi.org/10.1016/j.colsurfb.2020.111532
- 9. Braga S.S. // Biomolecules. 2019. V. 9. P. 801. https://doi.org/10.3390/biom9120801
- 10. Allahyari S., Trotta F., Valizadeh H. et al. // Expert Opin. Drug Deliv. 2019. V. 16. P. 467. https://doi.org/10.1080/17425247.2019.1591365
- 11. Mura P. // Int. J. Pharm. 2020. V. 579. P. 119181. https://doi.org/10.1016/j.ijpharm.2020.119181
- 12. Renard E., Deratani A., Volet G. et al. // Eur. Polum. J. 1997. V. 33. P. 49. https://doi.org/10.1016/S0014-3057 (96)00123-1
- 13. Di Cagno M., Nielsen T.T., Larsen K.L. et al. // Int. J. Pharm. 2014. V. 468. P. 258. https://doi.org/10.1016/j.ijpharm.2014.04.029
- 14. Vartak R., Patki M., Menon S. et al. // Ibid. 2020. V. 589. P. 119863. https://doi.org/10.1016/j.ijpharm.2020.119863
- 15. Zhang W., Gong X., Cai Y. et al. // Carbohydr. Polum. 2013. V. 95. P. 366. https://doi.org/10.1016/j.carbpol.2013.03.020
- 16. Дружининская О.В., Смехова И.Е. // Разработка и регистрация лекарственных средств. 2017. Т. 20. № 3. С. 144.
- 17. Amrhein J., Drynda S., Schlatt L. et al. // Int. J. Mol. Sci. 2020. V. 21. P. 6632. https://doi.org/10.3390/ijms21186632
- 18. Higuchi T., Connors K. // Adv. Anal. Chem. Instrum. 1965. V. 4. P. 117.
- 19. Dahan A., Miller J.M., Hoffman A. et al. // J. Pharm. Sci. 2010. V. 99. P. 2739–2749. https://doi.org/10.1002/jps.22033
